Literature DB >> 2292231

Hypnotics in the elderly. What cause for concern?

K Morgan1.   

Abstract

At any age hypnotic drug use can give rise to 3 major problems: unwanted effects on daytime mood and behaviour associated with drug consumption; rebound effects associated with drug withdrawal; and dependency associated with long term drug use. For 2 reasons elderly hypnotic users are both more vulnerable and more exposed to each of these problems. Firstly, age-related changes in pharmacodynamic and pharmacokinetic processes amplify the behavioural impact of many hypnotics; and secondly, age-related changes in the structure and quality of sleep tend to increase the demand for, and the long term use of, sedative hypnotic compounds in old age. The existence of physical illness, cognitive impairment, or daytime behaviour already compromised by normal aging processes further increases the likelihood of hypnotic drugs detrimentally affecting well-being in later life. These important causes for concern emphasise the need for 2 separate clinical responses: the need for greater circumspection in the choice and use of hypnotic drugs among elderly patients, and the need for a more broadly based clinical approach to the management of sleep problems in old age.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292231     DOI: 10.2165/00003495-199040050-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  56 in total

1.  Prevalence of sleep disturbance in a primarily urban Florida County.

Authors:  I Karacan; J I Thornby; M Anch; C E Holzer; G J Warheit; J J Schwab; R L Williams
Journal:  Soc Sci Med       Date:  1976-05       Impact factor: 4.634

2.  Patterns of benzodiazepine use in Great Britain as measured by a general population survey.

Authors:  G C Dunbar; M H Perera; F A Jenner
Journal:  Br J Psychiatry       Date:  1989-12       Impact factor: 9.319

3.  Chlordiazepoxide-induced hostility in a small group setting.

Authors:  C Salzman; G E Kochansky; R I Shader; L J Porrino; J S Harmatz; C P Swett
Journal:  Arch Gen Psychiatry       Date:  1974-09

4.  Effect of loprazolam and of triazolam on psychological functions.

Authors:  K Morgan; K Adam; I Oswald
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Anxiety caused by a short-life hypnotic.

Authors:  K Morgan; I Oswald
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-27

6.  Mania precipitated by benzodiazepine withdrawal.

Authors:  J Rigby; M Harvey; D R Davies
Journal:  Acta Psychiatr Scand       Date:  1989-04       Impact factor: 6.392

7.  Withdrawal from long-term benzodiazepine treatment.

Authors:  H Petursson; M H Lader
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-05

8.  Effect of flurazepam on sleep-disordered breathing and nocturnal oxygen desaturation in asymptomatic subjects.

Authors:  F R Dolly; A J Block
Journal:  Am J Med       Date:  1982-08       Impact factor: 4.965

9.  Pharmacokinetics and metabolism of zopiclone.

Authors:  J Gaillot; D Heusse; G W Hougton; J Marc Aurele; J F Dreyfus
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

10.  Quazepam and flurazepam: long-term use and extended withdrawal.

Authors:  A Kales; E O Bixler; C R Soldatos; A Vela-Bueno; J Jacoby; J D Kales
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

View more
  10 in total

1.  Hypnotics. Drug selection by means of the System of Objectified Judgement Analysis (SOJA) method.

Authors:  R Janknegt; A van der Kuy; G Declerck; C Idzikowski
Journal:  Pharmacoeconomics       Date:  1996-08       Impact factor: 4.981

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers.

Authors:  Ian Hindmarch; Eric Legangneux; Neil Stanley; Steve Emegbo; Jean Dawson
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

Review 4.  Clinical management of patients with insomnia. The role of zopiclone.

Authors:  G Hajak; A Rodenbeck
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

5.  Factors associated with low cognitive performance in general practice.

Authors:  M J Dealberto; B Sauron; C Derouesné; P Boyer; D Mayeux; F Piette; F Kohler; S Lubin; A Alpérovitch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

6.  Moderating Benzodiazepine Use in the Elderly: Curbing physicians' prescribing practices.

Authors:  P G Huston
Journal:  Can Fam Physician       Date:  1992-10       Impact factor: 3.275

Review 7.  Zopiclone: is there any dependence and abuse potential?

Authors:  M Lader
Journal:  J Neurol       Date:  1997-04       Impact factor: 4.849

Review 8.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 9.  Pharmacotherapy of insomnia: practice and prospects.

Authors:  J Dingemanse
Journal:  Pharm World Sci       Date:  1995-05-26

Review 10.  Guidelines for the rational use of benzodiazepines. When and what to use.

Authors:  H Ashton
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.